Pipeline — registered trials by phase
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
— · Non-small Cell Lung Cancer Metastatic · Active Not Recruiting · est. 2024-12
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where SOPHiA Genetics is lead sponsor; 1 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 6-K2026-08-04Report of foreign issuer
- 6-K2026-06-22Report of foreign issuer
- 6-K2026-06-22Report of foreign issuer
- 424B52026-06-17Prospectus (offering)
- 424B52026-06-16Prospectus (offering)
- 6-K2026-06-04Report of foreign issuer
- 6-K2026-05-19Report of foreign issuer
- 6-K2026-05-08Report of foreign issuer
- 6-K2026-05-05Report of foreign issuer
- EFFECT2026-03-06EFFECT
- 424B32026-03-06424B3
- CORRESP2026-03-04CORRESP
- UPLOAD2026-03-04UPLOAD
- F-32026-03-03F-3
- 20-F2026-03-03Annual report (foreign)
- 6-K2026-03-03Report of foreign issuer
- SCHEDULE 13G/A2026-02-11SCHEDULE 13G/A
- 6-K2026-01-28Report of foreign issuer
- 6-K2026-01-12Report of foreign issuer
- 6-K2026-01-12Report of foreign issuer
- 6-K2025-11-04Report of foreign issuer
- EFFECT2025-08-15EFFECT
- EFFECT2025-08-15EFFECT
- 424B52025-08-15Prospectus (offering)
- 424B32025-08-15424B3
- CORRESP2025-08-13CORRESP
- CORRESP2025-08-13CORRESP
- UPLOAD2025-08-12UPLOAD
- UPLOAD2025-08-12UPLOAD
- F-32025-08-05F-3
- F-32025-08-05F-3
- 6-K2025-08-05Report of foreign issuer
- S-82025-07-11Employee stock plan
- SCHEDULE 13G2025-06-27SCHEDULE 13G
- 6-K2025-06-18Report of foreign issuer
- 6-K2025-05-16Report of foreign issuer
- 6-K2025-05-08Report of foreign issuer
- 6-K2025-05-06Report of foreign issuer
- 20-F2025-03-04Annual report (foreign)
- 6-K2025-03-04Report of foreign issuer
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.